Droxi01 (Droxi01)
Droxidopa Capsule
Product Images NDC 67877-705
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Droxidopa (NDC 67877-705). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Droxi02 (Droxi02)
This data presents the baseline value of 5.1 and the units in both groups. It further describes the Mean Change in Dizziness due to the treatment of Droxidopa, which is -3.5. The other details include the weeks involved in the double-blind treatment phase, in which an assessment is done.*
Droxi03 (Droxi03)
The text appears to be a graph showing the percentage of subjects who experienced improvement in orthostatic hypotension symptom assessment (OHSA) question 1 after taking either Droxidopa medication or a placebo. The percentage improvement is shown on the vertical axis from 0 to 20, while the horizontal axis shows the weeks of the study. The medication Droxidopa displayed a higher percentage of improvement compared to the placebo.*
Droxidopa 100 mg 90s 1.jpg (Droxidopa 100 mg 90s 1)
Each capsule of Droxidopa medication contains 100 mg of the active ingredient. The recommended dosage information can be found in the prescribing information. The medication should be stored at a controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). It should be dispensed in a tight, light-resistant container. The packaging warns to keep out of reach of children and not to use if the capsule is broken or missing. The drug is manufactured by Akem Laboratories in Mumbai, India, and distributed by Ascend Laboratories in New Jersey with an NDC number of 67877-704-90. The text mentions an unvarnished area of 4528 mm and suggests that the rest of the label should be with UV varnish.*
Droxidopa 200 mg 90s.jpg (Droxidopa 200 mg 90s)
This is a prescription drug called Droxidopa and is available in capsule form. Each capsule contains 200 mg of droxidopa. The usual dosage of this medication should be prescribed by a doctor. It should be stored between 2°C to 25°C (36°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be stored in a light-resistant container. The capsule contains a pink seal under the cap to indicate authenticity. This medication should be kept out of reach of children. It is manufactured by Abem Laboratories Limited in Mumbai, India, and distributed by Ascend Laboratories LLC in New Jersey, USA. The product has an NDC number of 67877-705-90 1. There is some information about the label and size provided, but it is unclear.*
Droxidopa 300 mg 90s.jpg (Droxidopa 300 mg 90s)
Each capsule contains 300mg of droxidopa. The usual dosage and storage instructions are provided. The capsules should not be used if the seal is broken or missing. A warning to keep the capsules out of reach of children is included. The manufacturer is Alfem Laboratories Ltd. in Mumbai, India, and the distributor is Ascens Laboratories LLC in Parsippany, NJ. The NDC number is 67877-706-90. This information pertains to Rx-only Droxidopa capsules and is printed on a label that should be 45mm x 30mm with UV varnish.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
